How much do paid clinical trials in Grand Rapids pay?

Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.

Are clinical trials in Grand Rapids safe?

Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.

How do I join a study in Grand Rapids, MI?

Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.

How often do new paid studies open in Grand Rapids?

Constantly — trials open and close enrollment every week. This page is refreshed weekly from the NIH registry. Join the email alert to be notified when a new study opens within 30 miles of Grand Rapids.

Can I be in more than one clinical trial at a time?

Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Grand Rapids typically complete one or two studies per year.

Paid Clinical Trials Grand Rapids, MI — 465 Studies Recruiting (Oct 2026)

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

NK-Cell Lymphoma, NK-Cell Leukemia EARLY/Phase 1 Interventional 40 participants sought

Helen De Vos — Grand Rapids, Michigan (0.6 mi) · Sponsor: New York Medical College

See eligibility & contact on ClinicalTrials.gov (NCT03719105)

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 10,000 participants sought

Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT03851445)

Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

First Episode Psychosis Phase 4 Interventional 300 participants sought

InterAct of Michigan — Grand Rapids, Michigan (0.6 mi) · Sponsor: Northwell Health

See eligibility & contact on ClinicalTrials.gov (NCT04005378)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia Phase 2 Interventional 222 participants sought

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT06124157)

Multilevel Community-Centered Intervention to Reduce Pregnancy Related and Associated Morbidity and Mortality (PRAMM) Disparities

Provider Confidence, Provider Behavior N/A Interventional 480 participants sought

Strong Beginings — Grand Rapids, Michigan (0.6 mi) · Sponsor: Michigan State University

See eligibility & contact on ClinicalTrials.gov (NCT07025057)

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Solid Tumor, Non-Small-Cell Lung Cancer Phase 1 Interventional 364 participants sought

START Midwest — Grand Rapids, Michigan (0.6 mi) · Sponsor: Astellas Pharma Inc

See eligibility & contact on ClinicalTrials.gov (NCT07094204)

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma, Relapsed/Refractory Multiple Myeloma Phase 2 Interventional 100 participants sought

START Midwest — Grand Rapids, Michigan (0.6 mi) · Sponsor: C4 Therapeutics, Inc.

See eligibility & contact on ClinicalTrials.gov (NCT07284758)

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Focal Segmental Glomerulosclerosis N/A Interventional 35 participants sought

Helen DeVos Children's Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: Kaneka Medical America LLC

See eligibility & contact on ClinicalTrials.gov (NCT02235857)

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma Phase 2 Interventional 81 participants sought

Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05112601)

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 Phase 3 Interventional 1,209 participants sought

Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT05946213)

Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus

Systemic Lupus Erythematosus of Childhood (Disorder) N/A Interventional 175 participants sought

Helen Devos Children's Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: Michigan State University

See eligibility & contact on ClinicalTrials.gov (NCT06232304)

E-Mindfulness Approaches for Living After Breast Cancer

Breast Cancer, Depression Phase 3 Interventional 402 participants sought

Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT06748222)

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate Phase 2 Interventional 1,431 participants sought

Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center — Wyoming, Michigan (4.2 mi) · Sponsor: Eli Lilly and Company

See eligibility & contact on ClinicalTrials.gov (NCT07415044)

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Phase 1 Interventional 694 participants sought

START Midwest /ID# 248685 — Grand Rapids, Michigan (0.6 mi) · Sponsor: AbbVie

See eligibility & contact on ClinicalTrials.gov (NCT05005403)

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Childhood Medulloblastoma Phase 3 Interventional 225 participants sought

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: Children's Oncology Group

See eligibility & contact on ClinicalTrials.gov (NCT05382338)

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Fuchs Endothelial Corneal Dystrophy, Fuchs Phase 2 Interventional 28 participants sought

DTX-168-201 Study Site — Grand Rapids, Michigan (0.6 mi) · Sponsor: Design Therapeutics, Inc.

See eligibility & contact on ClinicalTrials.gov (NCT07024693)

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Cancer, Bladder Cancer Phase 2, Phase 3 Interventional 630 participants sought

Research Site — Grand Rapids, Michigan (0.6 mi) · Sponsor: Daiichi Sankyo

See eligibility & contact on ClinicalTrials.gov (NCT07129993)

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma Phase 3 Interventional 1,524 participants sought

Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology

See eligibility & contact on ClinicalTrials.gov (NCT07200830)

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Neuroblastoma Phase 2 Interventional 500 participants sought

Helen DeVos Children's Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: Giselle Sholler

See eligibility & contact on ClinicalTrials.gov (NCT02559778)

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive N/A Interventional 739 participants sought

Helen DeVos Children's Hospital at Spectrum Health — Grand Rapids, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT03723928)

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Advanced or Metastatic Colorectal Cancer Phase 1, Phase 2 Interventional 225 participants sought

Start Midwest — Grand Rapids, Michigan (0.6 mi) · Sponsor: Janssen Research & Development, LLC

See eligibility & contact on ClinicalTrials.gov (NCT05379595)

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma Phase 2 Interventional 396 participants sought

Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT05633615)

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Non-Small Cell Lung Cancer Phase 3 Interventional 675 participants sought

Research Site — Grand Rapids, Michigan (0.6 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT06357533)

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Relapsed/Refractory Acute Myeloid Leukemia Phase 1 Interventional 120 participants sought

START Midwest/The Cancer and Hematology Center — Grand Rapids, Michigan (0.6 mi) · Sponsor: SystImmune Inc.

See eligibility & contact on ClinicalTrials.gov (NCT06714591)

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Atopic Dermatitis N/A Observational 1,000 participants sought

Galderma Investigational Site 7108 — Grandville, Michigan (6.5 mi) · Sponsor: Galderma R&D

See eligibility & contact on ClinicalTrials.gov (NCT06988605)

Paid Clinical Trials in Grand Rapids, MI

Studies recruiting near Grand Rapids right now

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Multilevel Community-Centered Intervention to Reduce Pregnancy Related and Associated Morbidity and Mortality (PRAMM) Disparities

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus

E-Mindfulness Approaches for Living After Breast Cancer

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Studies you may be able to join near Grand Rapids

See which clinical studies you may qualify for

Top-rated research centers in Grand Rapids

MSU Grand Rapids Research Center

Cancer Research Consortium of West Michigan

West Michigan Clinical Research Center

Imperial Clinical Research Services

Beat Childhood Cancer Research Consortium

BAMF Health

The Cancer & Hematology Centers

Corewell Health Graduate Medical Education

Vivid IV Health

Clinical trials in Grand Rapids: what's recruiting

How to enroll in a paid study in Grand Rapids

Frequently asked questions

Paid clinical trials near Grand Rapids

By condition

More of MI

New paid studies open every week